JP2018520124A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520124A5
JP2018520124A5 JP2017563973A JP2017563973A JP2018520124A5 JP 2018520124 A5 JP2018520124 A5 JP 2018520124A5 JP 2017563973 A JP2017563973 A JP 2017563973A JP 2017563973 A JP2017563973 A JP 2017563973A JP 2018520124 A5 JP2018520124 A5 JP 2018520124A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
alkylene
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039270 external-priority patent/WO2016210275A1/en
Publication of JP2018520124A publication Critical patent/JP2018520124A/ja
Publication of JP2018520124A5 publication Critical patent/JP2018520124A5/ja
Pending legal-status Critical Current

Links

JP2017563973A 2015-06-26 2016-06-24 Nut正中線癌の治療 Pending JP2018520124A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
US62/185,203 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (2)

Publication Number Publication Date
JP2018520124A JP2018520124A (ja) 2018-07-26
JP2018520124A5 true JP2018520124A5 (cg-RX-API-DMAC7.html) 2019-07-25

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563973A Pending JP2018520124A (ja) 2015-06-26 2016-06-24 Nut正中線癌の治療

Country Status (14)

Country Link
US (1) US20180193350A1 (cg-RX-API-DMAC7.html)
EP (1) EP3314005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018520124A (cg-RX-API-DMAC7.html)
KR (1) KR20180035785A (cg-RX-API-DMAC7.html)
CN (1) CN107787227A (cg-RX-API-DMAC7.html)
AR (1) AR105124A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016283020A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017028178A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989313A1 (cg-RX-API-DMAC7.html)
HK (1) HK1252062A1 (cg-RX-API-DMAC7.html)
IL (1) IL256186A (cg-RX-API-DMAC7.html)
MA (1) MA42249A (cg-RX-API-DMAC7.html)
MX (1) MX2017016337A (cg-RX-API-DMAC7.html)
WO (1) WO2016210275A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
MX377534B (es) 2014-02-28 2025-03-10 Tensha Therapeutics Inc Compuestos para usarse en el tratamiento de hiperinsulinemia.
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
WO2024123929A1 (en) * 2022-12-06 2024-06-13 Bioventures, Llc Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
NZ599258A (en) 2009-11-05 2014-05-30 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102781943B (zh) 2009-11-05 2016-10-05 葛兰素史密丝克莱恩有限责任公司 苯并二氮杂*溴结构域抑制剂
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
BR122014024883A2 (pt) * 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
MX377534B (es) 2014-02-28 2025-03-10 Tensha Therapeutics Inc Compuestos para usarse en el tratamiento de hiperinsulinemia.

Similar Documents

Publication Publication Date Title
JP2018520124A5 (cg-RX-API-DMAC7.html)
JP2017515856A5 (cg-RX-API-DMAC7.html)
JP2017121233A5 (cg-RX-API-DMAC7.html)
JP2017521387A5 (cg-RX-API-DMAC7.html)
RU2016147742A (ru) Дейтрированные гетероциклические соединения и их применение в качестве средств визуализации
RU2016150404A (ru) Пирроло[2,3-с]пиридины в качестве визуализирующих агентов для нейрофибриллярных клубков
JP2016509047A5 (cg-RX-API-DMAC7.html)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2009528271A5 (cg-RX-API-DMAC7.html)
JP2011517683A5 (cg-RX-API-DMAC7.html)
JP2017537080A5 (cg-RX-API-DMAC7.html)
JP2019505529A5 (cg-RX-API-DMAC7.html)
JP2013544846A5 (cg-RX-API-DMAC7.html)
JP2017508789A5 (cg-RX-API-DMAC7.html)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2016513661A5 (cg-RX-API-DMAC7.html)
JP2016510326A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2016531871A5 (cg-RX-API-DMAC7.html)
JP2018507191A5 (cg-RX-API-DMAC7.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2015536997A5 (cg-RX-API-DMAC7.html)
JP2016522254A5 (cg-RX-API-DMAC7.html)
JP2017534664A5 (cg-RX-API-DMAC7.html)
JP2017530154A5 (cg-RX-API-DMAC7.html)